- Home
- APD vs REGN Comparison
APD vs REGN Comparison
Compare APD & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APD
- REGN
- Stock Information
- Founded
- APD 1940
- REGN 1988
- Country
- APD United States
- REGN United States
- Employees
- APD N/A
- REGN N/A
- Industry
- APD Major Chemicals
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- APD Industrials
- REGN Health Care
- Exchange
- APD Nasdaq
- REGN Nasdaq
- Market Cap
- APD 60.2B
- REGN 56.7B
- IPO Year
- APD 1987
- REGN 1991
- Fundamental
- Price
- APD $299.23
- REGN $563.10
- Analyst Decision
- APD Buy
- REGN Buy
- Analyst Count
- APD 15
- REGN 21
- Target Price
- APD $333.93
- REGN $823.86
- AVG Volume (30 Days)
- APD 1.0M
- REGN 928.0K
- Earning Date
- APD 07-31-2025
- REGN 08-01-2025
- Dividend Yield
- APD 2.39%
- REGN 0.62%
- EPS Growth
- APD N/A
- REGN 16.49
- EPS
- APD 6.88
- REGN 39.43
- Revenue
- APD $12,020,700,000.00
- REGN $14,085,700,000.00
- Revenue This Year
- APD $0.00
- REGN N/A
- Revenue Next Year
- APD $4.89
- REGN $6.77
- P/E Ratio
- APD $43.51
- REGN $14.29
- Revenue Growth
- APD N/A
- REGN 7.52
- 52 Week Low
- APD $243.69
- REGN $476.49
- 52 Week High
- APD $341.14
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- APD 65.81
- REGN 56.99
- Support Level
- APD $284.25
- REGN $541.50
- Resistance Level
- APD $300.52
- REGN $577.73
- Average True Range (ATR)
- APD 4.53
- REGN 14.97
- MACD
- APD 0.41
- REGN 1.85
- Stochastic Oscillator
- APD 92.07
- REGN 63.68
About APD Air Products and Chemicals Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $12.1 billion in revenue in fiscal 2024.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).